Methods
Daily intake of 12 SQ-HDM SLIT-tablet was investigated in the prospective, multi-center, observational study. It comprised 4 consultations in 1 year. Data on safety, tolerability, treatment satisfaction, symptomatic medication, compliance, and clinical effectiveness (Control of Allergic Rhinitis and Asthma Test; CARAT) were collected. Descriptive and longitudinal regression data analysis was performed.